Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6531737 | 0.72 | CTSL (0.43) | — | |
| SCHEMBL3718009 | 0.70 | SMN1; SMN2 (0.52) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL14350869 | 0.70 | MME (0.58) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL7649111 | 0.67 | CNR2 (0.50) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL7593794 | 0.67 | CTSL (0.46) | — | |
| SCHEMBL24414243 | 0.67 | MMP9 (0.54) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL7137335 | 0.65 | CNR2 (0.47) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL8980361 | 0.64 | CYP2C19 (0.32) | — | |
| SCHEMBL2543476 | 0.64 | SMN1; SMN2 (0.73) | SMN1; SMN2KMT2AMEN1HTTHPGD | |
| SCHEMBL15936045 | 0.64 | RAB9A (0.55) | SMN1; SMN2KMT2AMEN1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | SMN1; SMN2 4034/4885KMT2A 3705/4885MEN1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.